亿帆医药：自研项目亿立舒已于2023年度确认无形资产并计提减值准备

Core Viewpoint - Yifan Pharmaceutical (002019) has confirmed that its self-developed project Yilishu has recognized intangible assets and made impairment provisions for the fiscal year 2023, with no impairment signs detected so far [1] Group 1 - The company has reported that its ongoing research project F-652 is still in the development process and has not shown any signs of impairment this year [1]